

Ypsomed Holding AG
Brunnmattstrasse 6
PO Box
3401 Burgdorf / Switzerland
Tel. +41 34 424 41 11
Fax +41 34 424 41 55
www.ypsomed.com

PRESS RELEASE

Ypsomed concludes License Agreement on own auto-injector patents with major pharmaceutical company

Burgdorf, 22nd May 2007, 7:00am - Ypsomed is pleased to announce that it has granted to a major, globally acting pharmaceutical company a non exclusive license to use certain patents, which protect inventions of Ypsomed in the area of auto-injector technology. Ypsomed expects to receive several million Swiss Francs in license fees over the term of the concluded agreement.

Ypsomed is investing more than CHF 25 million annually in research and development of new products and technologies. Today Ypsomed possesses in the area of self-injection devices, pen systems and auto-injector technology more than 219 patent families including both granted and applied patents in numerous countries. Ypsomed owns 40 patent families in the area of auto-injector technology.

Richard Fritschi, CEO of Ypsomed, was extremely pleased: „This non exclusive license agreement is a major milestone for Ypsomed and demonstrates how valuable Ypsomed’s know-how and intellectual property are. Ypsomed will continue to protect their developments and technologies with patents and actively defend them.”

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG. Tel. +41 34 424 41 43 or Tel. +41 34 424 41 11. This press release and further documents are available in electronic form at www.ypsomed.com